治疗后鳞状细胞癌抗原可预测接受同步放化疗的宫颈鳞状细胞癌患者的治疗失败
本研究回顾性分析了2012年6月至2015年5月在本院接受根治性放疗或同步放化疗的559例宫颈鳞状细胞癌患者,采用ROC曲线确定治疗后鳞状细胞癌抗原预测治疗失败的最佳截断值为1.8 ng/mL(灵敏度27.1%,特异度96.6%)。多因素分析显示治疗后鳞状细胞癌抗原≥1.8 ng/mL是无病生存的独立预后因素(HR 5.10;95%CI 3.31-7.88;p<0.001),该组患者3年总生存、无病生存、局部控制和远处控制率均显著低于<1.8 ng/mL组。
要点
- 治疗后SCC Ag最佳截断值为1.8 ng/mL,灵敏度27.1%、特异度96.6%。
- 治疗后SCC Ag≥1.8 ng/mL是无病生存的独立预后因素(HR 5.10;95%CI 3.31-7.88;p<0.001)。
- SCC Ag≥1.8 ng/mL组3年总生存46.4%,<1.8 ng/mL组为90.7%(p<0.001)。
核心结论
- 治疗后SCC Ag≥1.8 ng/mL的患者治疗失败率高、生存差。
研究设计与样本
- 回顾性分析2012年6月至2015年5月在本院接受根治性放疗或同步放化疗的559例宫颈鳞状细胞癌患者。
主要发现
- ROC曲线确定治疗后SCC Ag最佳截断值为1.8 ng/mL,灵敏度27.1%、特异度96.6%。
- 47例患者治疗后SCC Ag≥1.8 ng/mL。
- 多因素分析显示治疗后SCC Ag为无病生存的独立预后因素(HR 5.10;95%CI 3.31-7.88;p<0.001)。
- SCC Ag<1.8 ng/mL组与≥1.8 ng/mL组的3年总生存率分别为90.7%和46.4%(p<0.001),无病生存率分别为84.8%和31.9%(p<0.001),局部控制率分别为81.4%和69.5%(p<0.001),远处控制率分别为90.4%和54.1%(p<0.001)。
关键数值与推荐
- 治疗后SCC Ag≥1.8 ng/mL预测治疗失败的灵敏度为27.1%、特异度为96.6%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the association between posttreatment squamous cell carcinoma antigen (SCC Ag) and treatment failure in patients with cervical SCC treated with concurrent chemoradiotherapy (CCRT). METHODS: We reviewed patients with cervical SCC who were treated with definitive radiotherapy or CCRT between June 2012 and May 2015 at our institute. A receiver operating characteristic (ROC) curve was used to analyze the cutoff value of posttreatment SCC Ag in predicting treatment failure. Log-rank tests and Cox proportional hazards models were used to identify whether posttreatment SCC Ag was significant in predicting disease-free survival (DFS). RESULTS: A total of 559 patients were included in this study. With the ROC curve, the optimal cutoff posttreatment SCC Ag level was 1.8 ng/mL (sensitivity 27.1%, specificity 96.6%). A posttreatment SCC Ag level ≥ 1.8 ng/mL was observed in 47 patients. The multivariate analysis showed that posttreatment SCC Ag (hazard ratio 5.10; 95% confidence interval, 3.31-7.88; p < 0.001) was an independent prognostic factor of DFS. The 3-year overall survival (OS), DFS, local control, and distant control rates of patients with posttreatment SCC Ag < 1.8 ng/mL and ≥1.8 ng/mL were 90.7% and 46.4% (p < 0.001), 84.8% and 31.9% (p < 0.001), 81.4% and 69.5% (p < 0.001), and 90.4% and 54.1% (p < 0.001), respectively. CONCLUSION: Patients with posttreatment SCC Ag ≥ 1.8 ng/mL suffer due to a high rate of treatment failure and poor survival.
引用
- Wang W, Liu X, Hou X, et al. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. Gynecol Oncol. 2019. PMID: 31500891. doi:10.1016/j.ygyno.2019.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。